Trento, Italy – Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, is one of the most devastating neurodegenerative disorders. By progressively destroying the motor neurons that control voluntary muscle movement, ALS gradually robs patients of their ability to walk, speak, swallow, and eventually breathe. While multidisciplinary care has significantly improved quality of life for many patients, effective treatments capable of halting or reversing disease progression remain elusive.
Yet, hope continues to grow. Over the past decade, advances in molecular biology, biomarker discovery, and precision medicine have transformed researchers’ understanding of ALS. Among the latest breakthroughs is an international study led by the University of Trento, offering new insight into one of the disease’s lesser-known players: glial cells.
Looking Beyond Motor Neurons
For decades, ALS research primarily focused on the degeneration of motor neurons. However, scientists are increasingly recognizing that these neurons do not act alone. They are surrounded by glial cells—particularly astrocytes and oligodendrocytes—which provide structural support, nutrients, and metabolic assistance necessary for healthy brain function.
The new study, published in Brain under the title “MYC-driven gliosis impairs neuron–glia communication in amyotrophic lateral sclerosis,” investigated how these supporting cells behave in slowly progressing forms of ALS.
The research brought together 51 scientists from Italy, Spain, the United Kingdom, the United States, Lebanon, and Japan, combining expertise from multiple disciplines and making extensive use of the advanced research facilities at the University of Trento’s Department of Cellular, Computational and Integrative Biology (CIBIO).
According to Professor Manuela Basso, the study’s corresponding author, the findings could significantly reshape scientists’ understanding of ALS progression and open new avenues for diagnosis and treatment.
When the Brain’s Support System Turns Against Itself
Under normal conditions, glial cells play an essential role in protecting and nourishing neurons. But the researchers discovered that, during ALS progression, these cells undergo dramatic biological changes.
In the early stages of slowly progressing ALS, glial cells temporarily revert to an immature state, allowing them to proliferate. This appears to be an adaptive response, as the cells initially attempt to compensate for neuronal damage and repair the surrounding tissue.
However, this protective strategy does not last.
As the disease advances, glial cells become highly inflammatory, creating an increasingly hostile environment for motor neurons. Instead of supporting neuronal survival, they lose their protective functions while simultaneously activating destructive biological processes that accelerate neurodegeneration.
“The glial cells are not simply bystanders,” explains Professor Basso. “They actively change their behavior throughout disease progression, profoundly influencing the fate of motor neurons.”
MYC: A Protein That Changes Everything
At the heart of the discovery lies MYC, a protein that normally regulates cell growth and gene expression.
The researchers found that MYC becomes abnormally hyperactive in ALS, fundamentally altering glial cell behavior.
Rather than maintaining healthy communication with neurons, MYC-driven glial cells promote inflammation and release tiny lipid-filled extracellular vesicles that, instead of nourishing motor neurons, contribute to their deterioration.
This breakdown in neuron–glia communication significantly compromises neuronal survival, suggesting that glial dysfunction is not merely a consequence of ALS but an active driver of disease progression.
Interestingly, the researchers propose that this abnormal MYC activation may stem from a genetic predisposition present specifically in ALS patients, although additional studies will be required to fully understand the underlying mechanisms.
Toward Personalized Medicine
Beyond explaining how ALS develops, the study may also influence how the disease is treated.
One of the greatest challenges facing clinicians is the remarkable variability among ALS patients. Some experience rapid decline, while others live with the disease for many years. According to Professor Basso, these differences may reflect distinct biological stages characterized by changing glial cell behavior.
This finding has important implications.
“If glial cells change their behavior throughout the course of the disease,” Basso explains, “we must identify these different stages early using reliable biomarkers so that patients can receive treatments specifically tailored to their condition.”
In other words, ALS may not be a disease that can be treated with a single universal therapy. Instead, future treatment strategies will likely involve personalized combination therapies, targeting multiple molecular pathways according to each patient’s disease stage.
A Step Closer to New Therapies
Although the discovery does not immediately translate into a cure, it represents an important milestone in ALS research.
By identifying MYC-driven gliosis as a critical mechanism disrupting communication between neurons and glial cells, scientists have uncovered a promising new therapeutic target. Future drugs designed to regulate MYC activity or restore healthy neuron–glia interactions could potentially slow—or even prevent—disease progression.
The findings also reinforce a growing consensus in neuroscience: neurodegenerative diseases are not solely disorders of neurons but involve complex interactions among multiple cell types within the nervous system.
The Road Ahead
Despite remarkable scientific progress, ALS remains an incurable disease. Nevertheless, studies such as this demonstrate how advances in molecular neuroscience are steadily revealing the biological processes that drive neurodegeneration.
As researchers continue to identify new biomarkers and therapeutic targets, the prospect of precision medicine for ALS comes increasingly into focus. While many challenges remain, international collaborations like the one led by the University of Trento offer renewed optimism that more effective—and ultimately disease-modifying—therapies may one day become a reality.
For the millions of patients, families, and clinicians affected by ALS, scientific research remains the strongest source of hope in the ongoing fight against this devastating disease.
Contact
Prof. Manuela Basso
Università di Trento
Phone: 0461 285219
Email: [email protected]